IL277577A - Antibody-based methods for the detection and treatment of Alzheimer's disease - Google Patents

Antibody-based methods for the detection and treatment of Alzheimer's disease

Info

Publication number
IL277577A
IL277577A IL277577A IL27757720A IL277577A IL 277577 A IL277577 A IL 277577A IL 277577 A IL277577 A IL 277577A IL 27757720 A IL27757720 A IL 27757720A IL 277577 A IL277577 A IL 277577A
Authority
IL
Israel
Prior art keywords
antibody
disease
detecting
based methods
treating alzheimer
Prior art date
Application number
IL277577A
Other languages
English (en)
Hebrew (he)
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of IL277577A publication Critical patent/IL277577A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL277577A 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease IL277577A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US201862703299P 2018-07-25 2018-07-25
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Publications (1)

Publication Number Publication Date
IL277577A true IL277577A (en) 2020-11-30

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277577A IL277577A (en) 2018-03-28 2020-09-24 Antibody-based methods for the detection and treatment of Alzheimer's disease

Country Status (12)

Country Link
EP (1) EP3774887A2 (https=)
JP (1) JP2021520777A (https=)
KR (1) KR20200144551A (https=)
CN (1) CN112236452A (https=)
AU (1) AU2019244481A1 (https=)
BR (1) BR112020018868A2 (https=)
CA (1) CA3095443A1 (https=)
IL (1) IL277577A (https=)
MX (1) MX2020009991A (https=)
RU (1) RU2020135052A (https=)
SG (1) SG11202008098TA (https=)
WO (1) WO2019186276A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
EP4028040A2 (en) 2019-09-09 2022-07-20 Axon Neuroscience SE Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4263599A1 (en) * 2020-12-16 2023-10-25 Voyager Therapeutics, Inc. Tau binding compounds
WO2022176959A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
CN117460954A (zh) * 2021-03-31 2024-01-26 华盛顿大学 作为tau蛋白病的生物标志物的CSF磷酸化tau和β-淀粉样蛋白概况
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
CN115078736B (zh) * 2022-06-24 2025-03-25 佛山市观迪医疗器械有限公司 一种用于阿尔茨海默症的均相免疫检测试剂盒
CN119836437A (zh) * 2022-08-19 2025-04-15 舒泰神(加州)生物科技有限公司 特异性识别程序性细胞死亡1配体1的抗体及其用途
CN117624351B (zh) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 一种抗人磷酸化tau181兔单克隆抗体及其应用
CN120118184A (zh) * 2023-12-08 2025-06-10 深圳湾实验室 靶向Tau的特异性结合蛋白及其应用
WO2025160022A1 (en) * 2024-01-26 2025-07-31 Beckman Coulter, Inc. Detecting phosphorylated tau (p-tau) 217 using chemiluminescent dioxetane compounds
CN119334929B (zh) * 2024-11-19 2026-02-24 中元汇吉生物技术股份有限公司 一种提升磷酸化tau蛋白检测灵敏度的方法及其试剂盒

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
WO1998022120A1 (en) * 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CN100572392C (zh) 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
CN101284136A (zh) 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
JP5599454B2 (ja) * 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US9371376B2 (en) * 2011-12-20 2016-06-21 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SI3221349T1 (sl) * 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
EP3412688A4 (en) * 2016-02-05 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. THROMBIN ANTIBODY, ANTIGENBINDING FRAGMENT, AND PHARMACEUTICAL USE THEREOF

Also Published As

Publication number Publication date
EP3774887A2 (en) 2021-02-17
KR20200144551A (ko) 2020-12-29
CN112236452A (zh) 2021-01-15
AU2019244481A1 (en) 2020-10-01
WO2019186276A8 (en) 2020-10-15
WO2019186276A2 (en) 2019-10-03
SG11202008098TA (en) 2020-10-29
RU2020135052A (ru) 2022-04-29
JP2021520777A (ja) 2021-08-26
BR112020018868A2 (pt) 2021-01-26
MX2020009991A (es) 2020-10-14
CA3095443A1 (en) 2019-10-03
WO2019186276A3 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
IL277577A (en) Antibody-based methods for the detection and treatment of Alzheimer's disease
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
IL254030B (en) Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications
IL277182A (en) Compositions and methods for treating Parkinson's disease
IL263433A (en) Methods for treating alzheimer's disease
SG11202011296VA (en) Compositions and methods for the treatment of parkinson's disease
EP3347486A4 (en) REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
DK3643321T3 (da) Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom
EP3558340A4 (en) METHOD FOR USE OF GM6 IN DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
EP3773500A4 (en) COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
MA45865A (fr) Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
EP3407858A4 (en) METHOD FOR TREATING THE APPEARANCE OF THINNING HAIR
PL3585373T3 (pl) Związki do stosowania w sposobach leczenia choroby Alzheimera
EP3398614A4 (en) AGENTS FOR PREVENTION AND / OR TREATMENT OF MORBUS ALZHEIMER
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
ZA202101489B (en) Compositions and methods for the treatment of parkinson's disease
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
EP3672619A4 (en) MATERIALS AND METHODS FOR EVALUATING CANCER RISK AND TREATING CANCER
IL274536A (en) Methods for prognosis or treatment of parkinson's disease
IL271637B (en) A factor in the prevention and/or treatment of Alzheimer's disease
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
IL265656A (en) Preparations and methods for the treatment of Alzheimer's disease and Parkinson's disease